Drug-induced ocular cicatrization.
Fiore
P M
PM
Glaucoma Consultation Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston 02114.
D001706:Biopsy; D003228:Conjunctiva / Q000473:pathology; D003229:Conjunctival Diseases / Q000139:chemically induced* / Q000473:pathology / Q000628:therapy; D004456:Echothiophate Iodide / Q000009:adverse effects; D004837:Epinephrine / Q000009:adverse effects; D006801:Humans; D007065:Idoxuridine / Q000009:adverse effects; D007165:Immunosuppression Therapy; D010390:Pemphigoid, Benign Mucous Membrane / Q000139:chemically induced* / Q000473:pathology / Q000628:therapy; D010862:Pilocarpine / Q000009:adverse effects; D000644:Quaternary Ammonium Compounds / Q000009:adverse effects; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced*; D013999:Timolol / Q000009:adverse effects; D014212:Tretinoin / Q000627:therapeutic use
D000644:Quaternary Ammonium Compounds; D010862:Pilocarpine; D014212:Tretinoin; D013999:Timolol; D004456:Echothiophate Iodide; C100193:demecarium; D007065:Idoxuridine; D004837:Epinephrine